The NFED’s decades-long effort to develop a potential treatment for x-linked hypohidrotic ectodermal dysplasia (XLHED) is coming closer to fruition.
Carline Durand and Agnes Jaulent, PhD from espeRare share the latest information (as of October 14, 2020) on the development of the protein ER-004 as a treatment for x-linked hypohidrotic ectodermal dysplasia (XLHED).
In this 31-minute webinar, they explain the history of the research that led to the development of ER-004. They talk about how the protein works to replace the protein missing in XLHED and the effect it has on the development of sweat glands, tooth buds, Meibomian glands and other body parts.
You will learn about…
- Dr. Holm Schneider’s Trial to Cure in which he treated three babies in-utero with ER-004 and how it affected them.
- the purpose of espeRare’s upcoming clinical study
- how long the study will begin and last
- who is eligible for the study
- where the study will take place
- how and when the treatment would be given
- the potential challenges of the study
- how they will assess the benefits of the treatment
- the side effects of the treatment
- when they will know if the study is successful
- how XLHED families have previously contributed to this research.
About the Experts
Caroline Durand trained as a pharmacist (France) and has a chemical engineer (école polytechnique de Montréal, Canada). She was previously in charge of pharmaceutical affairs for a French biotech company. She has 10+ years of experience in the field of development and biomanufacturing and has held various positions in R&D, industrialization, and analytical development at Sanofi Pasteur (Lyon, France). At Esperare, Caroline is in charge of developing clinical and regulatory strategies, interacting with Health Authorities (EU/US) and also leading the development of new clinical programs.
Agnes Jaulent is the Translational Project Leader for espeRare. She studied for her PhD in chemistry at Imperial College London and then completed her post doctoral studies at the LMB (Laboratory for Molecular Biology) in Cambridge, United Kingdom. She then joined a biotech company that specializes in offering discovery services to the pharma industry in the fields of peptide, protein and antibody discovery. She is an expert in all fields pertaining to protein and peptide chemistry. At EspeRare, Agnes is, amongst other duties, responsible for the CMC aspects of the ER-004 project.
Please fill out the following form to access the resource: